---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-113949"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:54:10.395250+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 4DMT FY2025 net loss $140M; cash $514M; 4D-150 Phase 3 enrollment completed

## Summary
- Net loss of $140M in FY2025 versus $161M in FY2024; R&D expenses $196M (up from $141M).
- Cash, equivalents and securities $514M; expected to fund operations into H2 2028.
- 4D-150 4FRONT-1 Phase 3 wet AMD enrollment completed; topline data expected H1 2027.
- Otsuka partnership for 4D-150 in Asia-Pacific provided $85M upfront; up to $336M milestones plus royalties.
- Leadership additions: new CFO Kristian Humer, CMO Julie Clark, CTO Katy Barglow, Board member Glenn Sblendorio.

## SEC filing metadata
- accession: 0001193125-26-113949
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/0001193125-26-113949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-20260318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-113949
- JSON: https://secwatch.observer/filing/0001193125-26-113949.json
- Plain text: https://secwatch.observer/filing/0001193125-26-113949.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.